Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.

ABSTRACT:

Background

A limitation of approved oncolytic viruses is their requirement for intratumoral (i.t.) injection. TILT-123 (igrelimogene litadenorepvec, Ad5/3-E2F-D24-hTNFα-IRES-hIL-2) is a chimeric oncolytic adenovirus suitable for intravenous (i.v.) delivery due to its capsid modification and dual selectivity devices. It is armed with tumor necrosis alpha and interleukin-2 for promoting T-cell activation and lymphocyte trafficking to tumors, thereby enhancing the antitumor immune response. Here, we present the findings after a single i.v. administration of TILT-123 in three phase I dose escalation clinical trials.

Methods

Patients with advanced solid tumors initially received a single i.v. dose of TILT-123 ranging from 3 × 10⁹ to 4 × 10¹² viral particles

SUBMITTER: Jirovec E 

PROVIDER: S-EPMC11539705 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature